All updates

All updates

icon
Filter
Funding
Cellino Biotech raises USD 80 million in Series A
AI Drug Discovery
Jan 25, 2022
This week:
Funding
Moment Energy secures USD 20.3 million in government funding from US Department of Energy
Alternative Energy
Yesterday
Funding
Fluence Energy raises USD 300 million in convertible notes to upgrade battery production
Alternative Energy
Yesterday
M&A
Coralogix acquires AI observability platform Aporia for USD 50 million
Generative AI Infrastructure
Dec 23, 2024
Product updates
Pimax announces compact Dream Air VR headset for USD 1,900
Extended Reality
Dec 23, 2024
Funding
HuLoop raises Series A funding from Mighty Capital
Workflow Automation Platforms
Dec 23, 2024
M&A
Fiserv to acquire Payfare for undisclosed sum to enhance embedded finance solutions
Financial Wellness Tools
Dec 23, 2024
M&A
Fiserv to acquire Payfare for undisclosed sum to enhance embedded finance solutions
FinTech Infrastructure
Dec 23, 2024
Funding
Meight raises EUR 3.4 million in funding led by Cusp Capital
Smart Mobility Information
Dec 23, 2024
Regulation/policy
Desktop Metal sues Nano Dimension over merger compliance
Additive Manufacturing
Dec 23, 2024
Management news
Nexa3D scales back operations amid financial crisis
Additive Manufacturing
Dec 23, 2024
AI Drug Discovery

AI Drug Discovery

Jan 25, 2022

Cellino Biotech raises USD 80 million in Series A

Funding

  • Massachusetts-based AI cell therapy company Cellino Biotech has raised USD 80 million in a Series A funding round led by Leaps by Bayer (the impact investment arm of Bayer AG) and Humboldt Fund. Among others, existing investor Khosla Ventures and new investor Felicis Ventures also participated in the round. 

  • The proceeds will be directed toward advancing its AI-based platform with improved machine learning and hardware capabilities to offer both autologous (using patient’s own cells) and allogeneic (using donor cells) therapies. The company also plans to build a good manufacturing practices (GMP) standard facility to assist in clinical trials. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.